|
|
|
| Analysis of expression and its clinical significance of UBE2T in lung cancer based on GEO database |
| 1LI Wei， 2GUO Zi-xing， 1LI Yong-hong， 2LIU Xiao-ping， 2HUANG Jing-yu， 2HU Wei-dong， 3，4LI Sheng |
| 1Department of Oncology， The First People’s Hospital of Tianmen， Tianmen 431700， Hubei， China； 2Department of Thoracic Oncology， Zhongnan Hospital of Wuhan University， Wuhan University，Wuhan 430071， Hubei， China； 3Department of Biological Repositories， Zhongnan Hospital of Wuhan University， Wuhan 430071， Hubei， China； 4Human Genetics Resource Preservation Center of Hubei Province， Wuhan 430071， Hubei， China |
|
|
|
|
Abstract Objective To investigate the expression of Ubiquitin-conjugating enzyme E2T(UBE2T) in lung cancer in the NCBI Gene Expression Omnibus (GEO) database and its relationship with clinicopathological characteristics and prognosis of lung cancer. Methods GEO datasets were collected and expression profile of UBE2T and clinicopathological information of lung cancer tissues were downloaded. The relationship between UBE2T expression and clinicopathological features (age， T stage， N stage， M stage， pathological type and recurrence) and prognosis of lung cancer were analyzed. Gene enrichment analysis (GSEA) was used to analyze genes regulated by UBE2T. Results The expression level of UBE2T in lung cancer tissues was 1.222±0.1214，higher than -1.645±0.0783 of normal bladder tissues， and the difference was statistically significant (P＜0.05). The expression of UBE2T in lung cancer tissues was related to T stage， N stage， pathological analysis and recurrence (P<0.05)， but not related to gender， age and M stage (P>0.05). The 5-year overall survival rate and 5-year disease-free survival rate of UBE2T high expression group were 32.672% and 27.513%， lower than 66.767% and 62.019% in the low-expression group， and the difference was statistically significant (P＜0.05). GSEA results showed that UBE2T highly expressed samples enriched MYC signaling pathway， DNA repair factor， mitotic spindle， G2M checkpoint， mTORC1 complex， E2F transcription factor and mitotic related gene sets. Conclusion UBE2T is highly expressed in lung cancer tissues and is related to many clinicopathological features of lung cancer. UBE2T could be considered as a potential marker and target in the diagnosis and treatment of lung cancer.
|
|
|
|
|
|
1.Freddie B， Jacques F， Isabelle S， et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018；68:394-424.
2.Torre LA， Siegel R ， Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016；893:1-19.
3.Amelio I， Vivien Landré， Knight RA， et al. Polypharmacology of small molecules targeting the ubiquitin-proteasome and ubiquitin-like systems. Oncotarget. 2015；6(12):9646-9656.
4.Wen M， Kwon Y， Wang Y， et al. Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer. Oncotarget. 2015；6(28):25226-25239.
5.Yu H， Xiang P， Pan Q， et al. Ubiquitin-conjugating enzyme E2T is an independent prognostic factor and promotes gastric cancer progression. Tumour Biol. 2016；37(9):11723-11732.
6.Gong Y， Peng D， Ning X， et al. UBE2T silencing suppresses proliferation and induces cell cycle arrest and apoptosis in bladder cancer cells. Oncol Lett. 2016；12(6):4485-4492.
7.Ueki T， Park JH， Nishidate T， et al. Ubiquitination and downregul-ation of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human breast cancer cells. Cancer Res. 2009；69(22):8752-8760.
8.袁佳仪，何恒晶，毕娅琼，等. TOP2A基因表达对膀胱癌的预后价值分析. 国际肿瘤学杂志. 2018；45(1):22-26.
9.Jun H， Joachim A， Bianca DH， et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One. 2010；5(4):e10312.
10.Rousseaux S， Debernardi A， Jacquiau B， et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med. 2013；5(15):186ra66.
11.宋达为，黄睿，汤庆超，等. 利用GEO数据库分析结肠癌中EZH2及其相关基因的表达与意义. 中华结直肠疾病电子杂志. 2016；5(6):476-480.
12.Bi Y， Chen S， Jiang J， et al. CDCA8 expression and its clinical relevance in patients with bladder cancer. Medicine. 2018；97(34)：e11899.
13.冯雨嘉，蒋佳志，晏鑫， 等. 使用GEO数据集分析驱动蛋白KIF2C在膀胱癌中的表达及临床意义. 转化医学杂志. 2019；8(1):15-18.
14.Zhou MJ， Chen FZ， Chen HC. Ubiquitination involved enzymes and cancer. Med Oncol. 2014；31(8):93.
15.Joenje H， Patel KJ. The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet. 2001；2(6):446-459.
16.陈圳川，冷泠，季守平. 泛素/类泛素化调控DNA损伤修复机制研究进展. 生物技术通讯. 2017；28(2):169-174.
17.Machida YJ， Machida Y， Chen Y， et al. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell. 2006；23(4):589-596.
18.Rickman K， Lach F， Abhyankar A， et al. Deficiency of UBE2T， the E2 ubiquitin ligase necessary for FANCD2 and FANCI ubiquitination， causes FA-T subtype of Fanconi anemia. Cell Rep. 2015；12(1):35-41.
19.Brand TM， Iida M， Luthar N， et al. Nuclear EGFR as a molecular target in cancer. Radiother Oncol. 2013；108(3):370-377.
20. Alfpi F， Chaugule V， Walden H. Mechanism and disease association of E2-conjugating enzymes: lessons from UBE2T and UBE2L3.Biochem J. 2016；473(20):3401-3419.
21.Corson TW， Huang A， Tsao MS， et al. KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene. 2005；24(30):4741-4753. |
|
|
|
